Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market By 2029?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market size has seen substantial growth in recent years. It is anticipated to increase from $2 billion in 2024 to $2.59 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 29.7%. The expansion observed in the preceding period can be linked to the escalating incidence of non-alcoholic steatohepatitis, evolving dietary habits, increased consumption of processed foods, inactive lifestyles, and a rising prevalence of metabolic conditions.
The metabolic dysfunction-associated steatohepatitis (mash) treatment market size is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $7.29 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 29.5%. This expected growth during the forecast period can be attributed to the increasing prevalence of obesity and related diseases, early intervention initiatives, robust reimbursement mechanisms, comprehensive insurance coverage, and a heightened awareness of liver conditions. Prominent trends for the forecast period include an escalation in technological progress, the development of new treatments in the pipeline, the formation of strategic collaborations and partnerships, the advancement of personalized medicine and precision therapeutics, and increased investment in clinical trials and research efforts.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What Are The Key Drivers Of Growth In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The anticipated expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market is attributed to the rising incidence of obesity. Obesity, defined as an excessive accumulation of body fat that can adversely affect general health, is generally identified by a body mass index (BMI) of 30 or greater. Globally, the occurrence of obesity is increasing, fueled by inactive lifestyles, poor dietary habits, and various metabolic risk factors. In the context of obesity, the management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) primarily aims to tackle insulin resistance, decrease hepatic fat, and enhance metabolic well-being through modifications in lifestyle and specific therapeutic interventions. As an illustration, data from March 2023, provided by the World Heart Foundation, a global cardiovascular non-governmental organization based in Switzerland, indicates that around 2.3 billion adults and children globally are presently categorized as obese or overweight. This figure is expected to climb to 2.7 billion by 2025, given the current trajectory of obesity. Consequently, the rising occurrence of obesity is stimulating expansion within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
What Are The Emerging Segments Gaining Attention In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (mash) treatmentmarket covered in this report is segmented –
1) By Treatment: By Drug; By Therapy
2) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-User
3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents; Antidiabetic Drugs; Lipid-Lowering Agents; Vitamin E; Obeticholic Acid (OCA); GLP-1 Agonists; Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy; Lifestyle Modifications (Dietary Changes, Exercise); Bariatric Surgery; Liver Transplantation
How Are Emerging Market Trends Shaping The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry Landscape?
Leading companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating on developing innovative products, such as liver fibrosis treatment solutions, to offer therapeutic options for patients afflicted with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. These liver fibrosis treatment solutions aim to tackle the fundamental causes of liver damage through methods including lifestyle modifications, antiviral medications, and emerging antifibrotic therapies, with the goal of halting or reversing fibrosis progression and enhancing liver function. As an illustration, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), which stands as the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra, a daily oral tablet, demonstrated its effectiveness in resolving MASH without exacerbating fibrosis and improved liver fibrosis in phase 3 clinical trials. This pivotal development presents a non-invasive treatment alternative, removing the necessity for liver biopsies, and considerably enhances patient access and outcomes in managing fatty liver disease.
Who Are The Top Performing Companies In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market In Recent Years?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Industry Expansion?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2025, By The Business Research Company
Metabolic Disorders Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report
Cardiometabolic Diseases Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report
Comprehensive Metabolic Panel Cmp Testing Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model